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NUCLEOTIDE (DNA) SEQUENCE FOR CITRUS VALENCENE SYNTHASE
GENE (CVS)
SEQIDNO.: 1
LENGTH: 1710 NT

M
1~
1~

1~
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~
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10~
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15M
1549
1594
1~9

1684

ATGTCGTCTGGAGAAACATTTCGTCCTACTGCAGATTTCCATCCT
AGTTTATGGAGAAACCATTTCCTCAAAGGTGCTTCTGATTTCAAG
ACAGTTGATCATACTGCAACTCAAGAACGACACGAGGCACTGAAA
GAAGAGGTAAGGAGAATGATAACAGATGCTGAAGATAAGCCTGTT
CAGAAGTTACGCTTGATTGATGAAGTACAACGCCTGGGGGTGGCT
TATCACTTTGAGAAAGAAATAGAAGATGCAATACTAAAATT ATGT
CCAATCTATATTGACACTAATAGAGCTGATCTCCACACCGTTTCC
CTTCATTTTCGATTGATTAGGCAGCAAGGAATCAAGATTTCA TGT
GATGTGTTTGAGAAGTTCAAAGATGATGAGGGTAGATTCAAGTCA
TCGTTGATAAACGATGTTCAAGGGATGTTAAGTTTGTACGAGGCA
GCAT ACATGGCAGTTCGCGGAGAACAT ATA TTAGATGAAGCCATT
GCTTTCACTACCACTCACCTGAAGTCA TTGGTAGCTCAGGATCAT
GTAACCCCTAAGCTTGCGGAACAGATAAATCATGCTTTATACCGT
CCTCTTCGTAAAACCCTACCAAGATTAGAGGCGAGGTATTTTATG
TCCATGATCAATTCAACAAGTGATCATTT ATACAATAAAACTCTG
CTGAATTTTGCAAAGTTAGA TTTT AACATATTGCT AGAGCCGCAC
AAGGAGGAACTCAATGAATTAACAAAGTGGTGGAAAGATTTAGAC
TTCACTACAAAACTACCTTATGCAAGAGACAGATTAGTGGAGTTA
TAZTTTTGGGATTT AGGGACATACTTCGAGCCTCAAT ATGCATTT
GGGAGAAAGATAATGACCCAATTAAATTACATATTATCCATCATA
GATGATACTTATGATGCGTATGGTACACTTGAAGAACTCAGCCTC
TTTACTGAAGCAGTTCAAAGATGGAATATTGAGGCCGT AGATATG
CTTCCAGAATACATGAAATTGATTTACAGGACACTCTTAGATGCT
TTTAATGAAATTGAGGAAGATATGGCCAAGCAAGGAAGATCACAC
TGCGTACGTTATGCAAAAGAGGAGAATCAAAAAGTAATTGGAGCA
TACTCTGTTCAAGCCAAATGGTTCAGTGAAGGTT ACGTTCCAACA
ATTGAGGAGTATATGCCTATTGCACTAACAAGTTGTGCTTACACA
TTCGTCATAACAAATTCCTTCCTTGGCATGGGTGA TTTTGCAACT
AAAGAGGTTTTTGAATGGATCTCCAAT AACCCTAAGGTGTTAAAA
GCAGCATCAGTTATCTGCAGACTCATGGATGACATGCAAGGTCAT
GAGTTTGAGCAGAAGAGAGGACATGTTGCGTCAGCTATTGAATGT
TACACGAAGCAGCATGGTGTOTCTAAGGAAGAGGCAATTAAAATG
TTTGAAGAAGAAGTTGCAAATGCATGGAAAGATATTAACGAGGAG
TTGATGATGAAGCCAACCGTCGTTGCCCGACCACTGCTCGGGACG
A TTCTT AA TCTTGCTCGTGCAATTGATTTT ATTTACAAAGAGGAC
GACGGCTATACGCATTCTTACCTAATTAAAGATCAAATTGCTTCT
G T G C TAG GAG A C C A C G T T C CAT T T T G A 1710
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AMINO ACID SEQUENCE OF CITRUS VALENCENE SYNTHASE (CVS)
SEQIDN0.:4
LENGTH; 548 AA
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SESQUITERPENE SYNTHASE GENE AND
PROTEIN

natural orange essence oil with a solvent gas having a
temperature between its critical temperature and 100° C.,
and having a reduced pressure between about 0.56 and about
1.31 (where reduced pressure is defined as the extraction
pressure of the solvent gas divided by its critical pressure),
to extract flavor and aroma compounds; (b) separating the
solvent gas and dissolved compounds from the remaining
undissolved compounds; and (c) separating the dissolved
compounds from the solvent gas.
Rich, in U.S. Pat. No. 4,973,485, discloses a method of
producing aqueous orange stripper essences and orange
stripper oils with high ratios of valencene to the less desirable orange flavor compounds. This procedure involves the
following steps: (a) heating an orange fed juice stream to a
temperature of37.7° C. to 71° C.; (b) stripping the heated
feed juice with steam at a steam: soluble solids ratio of 0.3
to 1.5, at a temperature of 37.7° C. to 71 o C. and at a
stripping colunm pressure of less than 9 inches of Hg,
absolute; (c) condensing the stripped volatiles at a temperature of 40.6° C. to -196° C.; (d) centrifuging the condensate
in a continuous stacked disk hermetic centrifuge to produce
two clear phases; and (e) removing the aqueous orange
stripper essence phase.
In U.S. Pat. No. 5,260,086 Downton et a!. describe a
process for making an aseptic citrus sensible pulp/juice
slurry by extracting and removing juice from citrus juice
containing sensible pulp. After this process is complete,
flavorants, such as valencene are added to make up for those
that are lost during this extraction process.
Hiramoto et a!., in U.S. Pat. No. 6,495,193 prepares a
citrus flavor from a low-boiling part of a cold pressed oil by
a hydrate alcohol solvent extraction. To maintain the stability of the flavor, a stabilizing coumarin analogue component
is added.
In a US Patent Application, publication number US
20030185956, Gradley claims a separation method for
extracting desired sesquiterpene aroma compounds, such as
valencene and nootkatone, from an aqueous phase by separating the aqueous mixture from a water-immiscible hydrophobic phase by means of a hydrophilic membrane and
allowing the desired components to move out off the aqueous phase through the membrane and into the hydrophobic
phase.
Kotachi et a!., in US Patent Application, publication
number 20030203090, teaches of a process for preparing
orange oil useful as fragrance or flavor material, by mixing
raw material oil containing valencene with a high-boiling
solvent having a boiling point exceeding 240° C. under
normal pressure, to give a mixture, and fractionally distilling
the mixture obtained.
Nootkatone is a high demand, high value flavorant added
to many of the commercial soft drinks sold worldwide.
Currently, the practice of extracting nootkatone from citrus
pulp and rind is considered an expensive and somewhat
unreliable process. Nootkatone can be synthesized by the
oxidation of valencene. The valencene starting material is
expensive and is easily degraded during evaporative heat
concentration processes typically used to remove the bulk of
water from the feed juice. Thus, current methods to purifY
valencene from citrus fruits are costly, difficult, and are
limited by what the fruit can deliver. Moreover, such methods are vulnerable to interruptions in the supply of citrus
fruits, which is dependent on the weather. A frost or hailstorm in a major citrus fruit growing region such as Florida
can interrupt the supply. Furthermore, methods to produce
nootkatone that consume valencene are quite costly, and thus

RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 13/385,794, filed Mar. 6, 2012, now allowed,
which is a continuation of U.S. patent application Ser. No.
12/259,497, filed Oct. 28, 2008, now U.S. Pat. No. 8,192,
950, issued Jun. 5, 2012, which is a continuation of U.S.
patent application Ser. No. 10/899,356, filed on Jul. 26,
2004, now U.S. Pat. No. 7,442,785, issued Oct. 28, 2008,
which claims benefit of priority to U.S. Provisional Application No. 60/489,514, filed Jul. 24, 2003. The subject
matter of each of the above-referenced applications is herein
incorporated by reference in its entirety.
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FIELD OF THE INVENTION
This invention relates generally to the field of production
of valencene and nootkatone, and more particularly relates
to the discovery of a valencene synthase gene and related
protein, which provides a pathway for generating highly
pure valencene which can be converted into the flavorant,
nootkatone.

20

25

BACKGROUND
Terpenes are a diverse family of compounds with carbon
skeletons composed of five-carbon isoprene units. Approximately 20,000 different terpenes and terpenoids (compounds
of terpene origin whose carbon skeleton has been altered or
rearranged) have been identified to date, representing only a
small fraction of the estimated natural variation. Terpenes
are commonly isolated from the essential oils of plants.
Essential oils often have pleasant tastes or aromas, and they
are widely used as flavorings, deodorants, and medicines.
Sesquiterpenes are terpenes with 15 carbon atoms (three
isoprene units). The plant kingdom contains the highest
diversity of sesquiterpenes. Often they play a role in defense
of the plants against pathogens, insects and herbivores and
for attraction of pollinating insects.
Valencene (1,2,3,5,6,7,8,8a-octahydro-7 -isopropenyl-1,
Sa-dimethyl-naphthalene) and nootkatone (4,4a,5,6,7,8hexahydro-6-isopropenyl-4,4a-dimethyl-2(3H)-naphtalenone) are just two examples of sesquiterpenes that are
derived from cyclization of the ubiquitous pyrophosphate
intermediate farnesyl diphosphate. Nootkatone is formed by
the oxidation of valencene.
Valencene and nootkatone are compounds of natural
origin, and are natural constituents of citrus oils, such as
orange and grapefruit. Because of its excellent organoleptic
qualities and in particular its typical grapefruit taste, nootkatone is a widely used ingredient in perfumery and the
flavor industry. Alternatively, nootkatone may be used as an
insecticide. Valencene, the starting material for the generation of nootkatone (either biologically or chemically), is also
used as a flavorant and fragrance.
Several methods to purify sesquiterpenes, such as valencene and nootkatone, from citrus fruits or to maintain high
levels of these sesquiterpenes in citrus fruit extracts have
been described in the prior art. These methods are described
below.
Japikse et a!., in U.S. Pat. No. 4,693,905, claimed a
method of extracting concentrated orange flavor and aroma
compositions from natural orange essence oil by using a
dense solvent gas. Their procedure entailed (a) contacting
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3
not connnercially desirable. Therefore, there is a need for an
alternative means for preparing valencene and nootkatone.

4

sequence under conditions conducive to the production of
said at least one sesquiterpene synthase. In one embodiment,
the at least one nucleic acid is chosen from (a) a nucleic acid
SUMMARY OF THE INVENTION
comprising the nucleotide sequence substantially as set out
in SEQ ID N0:1, SEQ ID NO.: 5 or SEQ ID NO.: 6; (b) a
In one embodiment, the invention relates to isolated
nucleic acid encoding the polypeptide substantially set out in
nucleic acids that encode a sesquiterpene synthase. The
SEQ ID NO: 4, SEQ ID NO.: 7 or SEQ ID NO.: 8; and (c)
invention provides an isolated nucleic acid selected from: (a)
a nucleic acid that hybridizes to the nucleic acid of (a) or (b)
a nucleic acid comprising the nucleotide sequence substanunder low stringency conditions, wherein the polypeptide
tially as set out in SEQ ID NO: 1; (b) a nucleic acid encoding 10 encoded by said nucleic acid is a sesquiterpene synthase.
the polypeptide substantially set out in SEQ ID NO: 4; and
The host may be chosen from, for example, plants, micro(c) a nucleic acid that hybridizes to the nucleic acid of (a) or
organisms, bacterial cells, yeast cells, plant cells, and animal
(b) under low stringency conditions, wherein the polypepcells.
tide encoded by said nucleic acid is a sesquiterpene synIn another embodiment the invention provides a method
thase. Other embodiments include: a polypeptide encoded 15 of making at least one terpenoid comprising:
by a nucleic acid of the invention; a host cell comprising a
1) contacting at least one acyclic pyrophosphate terpene
nucleic acid of the invention; a non-human organism modiprecursor with at least one polypeptide encoded by a
fied to harbor a nucleic acid of the invention; and methods
nucleic acid of the current invention. In one embodiment,
of producing a polypeptide comprising culturing host cells
the nucleic acid is chosen from (a) a nucleic acid comof the invention.
20
prising the nucleotide sequence substantially as set out in
In another embodiment, the invention provides an isolated
SEQ ID NO.: 1, SEQ ID NO.: 5 or SEQ ID NO.: 6; (b)
polypeptide comprising an amino acid sequence substana nucleic acid encoding the polypeptide substantially set
tially as set out in SEQ ID NO: 4.
out in SEQ ID NO: 4, SEQ ID NO.: 7 or SEQ ID NO.: 8;
In a further embodiment, the invention provides a vector
and (c) a nucleic acid that hybridizes to the nucleic acid
comprising at least one nucleic acid chosen from (a) a 25
of (a) or (b) under low stringency conditions, wherein the
nucleic acid comprising the nucleotide sequence substanpolypeptide encoded by said nucleic acid is a sesquitertially as set out in SEQ ID NO: 1; (b) a nucleic acid encoding
pene synthase,
the polypeptide substantially set out in SEQ ID NO: 4; and
2) isolating at least one terpenoid produced in 1).
(c) a nucleic acid that hybridizes to the nucleic acid of (a) or
In one embodiment, the at least one terpenoid is chosen
(b) under low stringency conditions, wherein the polypep- 30 from the group consisting of sesquiterpene.
tide encoded by said nucleic acid is a sesquiterpene synIn a further embodiment, the at least one acyclic pyrothase. Other embodiments include, methods of making a
phosphate terpene precursor is farnesyl-diphosphate (FPP).
recombinant host cell comprising introducing a vector of the
The sesquiterpene produced by the methods of the invention
invention into a host cell.
include, but are not limited to, valencene, valencene derivaIn a further embodiment, the invention relates to isolated 35 tives, valencene fragments, and compounds having the citrus
nucleic acids that encode a sesquiterpene synthase. The
valencene carbon skeleton.
invention provides an isolated nucleic acid selected from: (a)
BRIEF DESCRIPTION OF THE DRAWINGS
a nucleic acid comprising the nucleotide sequence substantially as set out in SEQ ID NO: 5 or SEQ ID NO.: 6; (b) a
nucleic acid encoding the polypeptide substantially set out in 40
FIG. 1 shows the conversion of FPP to the sesquiterpene
SEQ ID NO: 7 or SEQ ID NO.: 8; and (c) a nucleic acid that
reaction products 5-epi-aristolochene, premnaspirodiene
hybridizes to the nucleic acid of (a) or (b) under low
and valencene catalyzed by Nicotiana tabacum epi-aristostringency conditions, wherein the polypeptide encoded by
lochene synthase (TEAS), Hyoscyamus muticus premsaid nucleic acid is a sesquiterpene synthase. Other embodinaspirodiene synthase (HPS), and Citrus paradisi valencene
ments include: a polypeptide encoded by a nucleic acid of 45 synthase (CVS), respectively.
FIG. 2 illustrates a mechanism for the enzyme catalyzed
the invention; a host cell comprising a nucleic acid of the
development of regia- and enantio-specificity in eremophiinvention; a non-human organism modified to harbor a
lanes. Upon loss of the diphosphate from C1 and generation
nucleic acid of the invention; and methods of producing a
polypeptide comprising culturing host cells of the invention.
of the initial carbocation, a chiral center arises from the first
In another embodiment, the invention provides an isolated 50 attack on either the si or re face of sp2 hybridized C10
polypeptide comprising an amino acid sequence substanyielding either (1 OR)-germacrene A or (10S)-germacrene A.
tially as set out in SEQ ID NO: 7 or SEQ ID NO.: 8.
Two additional chiral centers develop upon formation of an
In a further embodiment, the invention provides a vector
internal bond between C2 and C7. This process of protoncomprising nucleic acid chosen from (a) a nucleic acid
initiated, internal cyclization (illustrated as transition states)
comprising the nucleotide sequence substantially as set out 55 requires that the p-orbitals of sp2 hybridized C2 and C7 face
and align with each other. The 4 possible combinations of
in SEQ ID NO: 5 or SEQ ID NO.: 6; (b) a nucleic acid
encoding the polypeptide substantially set out in SEQ ID
overlapping orbitals are dependent on the orientation of the
NO: 7 or SEQ ID NO.: 8; and (c) a nucleic acid that
respective p orbitals either above or below the plane of the
hybridizes to the nucleic acid of (a) or (b) under low
eudesmalyl carbocation intermediate. The possible re and si
stringency conditions, wherein the polypeptide encoded by 60 orientations of the C2 p-orbitals are given on the vertical
axis of the diagram and those for C7 depicted on the
said nucleic acid is a sesquiterpene synthase. Other embodihorizontal axis. These orientations direct the stereochemisments include, methods of making a recombinant host cell
comprising introducing a vector of the invention into a host
try of the ensuing methyl migrations and hydride shifts (not
cell.
illustrated) and define, as a consequence, the final chirality
In one embodiment, the invention provides a method of 65 of the methyl substitutions at C2 and C3. Subsequent to
these rearrangements, a tertiary carbocation centered at C7
making at least one sesquiterpene synthase comprising culis formed (an eremophilyl cation, not shown) and alternate
turing a host cell modified to contain at least one nucleic acid
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elimination of a proton from C6 or C8 give two subclasses
of double bond regioisomers, illustrated as layers. Known
eremophilanes are noted by their common name.
FIG. 3 illustrates a proposed pathway for the biosynthesis
of nootkatone in citrus. The scheme suggests at least two
steps, the first step is catalyzed by the sesquiterpene synthase
of the current invention, denoted as "1" in the figure, which
leads to the production of valencene and the second step
consisting of a regia-specific hydroxylation, followed by
oxidation. The second step could be catalyzed by a single
multifunctional hydroxylase or could involve sequential
enzyme mediated reactions, and which are denoted as "2" in
the figure.
FIG. 4 illustrates a sequence alignment of amino acids
lining the active site (1st tier) and those within 3 A of the
active site residues (2nd tier) of TEAS with the corresponding positions of CVS. For uniformity, the TEAS amino acids
numbering was used, and thus the corresponding CVS
amino acids renumbered-termed comparative numbering.
The 1st tier residues lie within 3 A of a substrate analog
co-crystallized within the TEAS enzyme and includes residues making up the J/K loop which clamps down over the
active site upon substrate binding. The corresponding residues within CVS (valencene synthase) were initially identified by primary sequence alignment, then visual inspection
of the relevant CVS sequences overlaid on the TEAS
3-dimensional structure. Residues different from TEAS are
highlighted.
FIG. 5 shows SEQ ID NO.: 1, which is the DNA sequence
for the citrus valencene synthase gene from Citrus paradis
isolated in the current invention.
FIG. 6 shows SEQ ID NO.: 4, which is the protein
sequence for the citrus valencene synthase from Citrus
paradisi.
FIG. 7 illustrates reaction product analysis of citrus val encene synthase (CVS) incubated at pH 7.5. Lysate of E. coli
expressing the CVS eDNA was incubated with FPP at pH
7.5 and total pentane extractable products evaluated by
GC-MS (upper panel). The mass spectrum of the reaction
product corresponding to peak A (middle panel) is compared
to that of authentic valencene in the lower panel. The mass
spectrum of peak B is identical to that for beta-elemene, the
thermal-induced rearrangement product of germacrene A.
FIG. 8 illustrates a mass spectrum for the peak with a
retention time of7.38 minutes from FIG. 7 (top) compared
to the spectra for beta-elemene published by the NIST
library (bottom).
FIG. 9 illustrates mass spectrum for the peak with a
retention time of 8.89 in FIG. 7 (top) compared to that for
valencene purchased from Fluka Chemical Company (bottom).
FIG. 10 illustrates that the reaction product specificity of
citrus valencene synthase (CVS) is pH dependent. Partially
purified synthase isolated from E. coli expressing the CVS
eDNA was incubated with FPP at the indicated pH values
and ethylacetate extracts were examined directly by GCMS. Absolute values for valencene (solid symbols) and
germacrene A (measured as the thermally rearranged product ~-elemene) (open symbols) are reported and represent
greater than 95% of the total reaction products at all pHs.
FIG. 11 is a sequence aligument of amino acids lining the
active site (1st tier) of TEAS with the corresponding positions of HPS and CVS. The 1st tier residues lie within 3 A
of a substrate analog co-crystallized within the TEAS
enzyme and includes residues making up the J/K loop which
clamps down over the active site upon substrate binding.
The corresponding residues within the other terpene syn-

thases were initially identified by primary sequence alignment, then visual inspection of the relevant sequences overlaid on the TEAS 3-dimensional structure. Residues in CVS
differing from TEAS are highlighted.
FIG. 12 shows SEQ ID NO.: 5, which is the DNA
sequence from SEQ ID NO.: 1 corresponding to the amino
acids forming Tier 1. Comparative numbering from Tier 1
amino acid residues is also shown (SEQ ID NO.: 7).
FIG. 13 shows SEQ ID NO.: 6, which is the DNA
sequence from SEQ ID NO.: 1 corresponding to the amino
acids forming Tier 2. Comparative numbering from Tier 2
amino acid residues is also shown (SEQ ID NO.: 8).
FIG. 14a shows the absolute amino acid sequence from
SEQ ID NO.: 4 corresponding to the Tier 1 amino acid
residues. FIG. 14b shows the comparative amino acid
sequence of the Tier 1 amino acid residues (SEQ ID NO.: 7)
FIG. 15a shows the absolute amino acid sequence from
SEQ ID NO.: 4 corresponding to Tier 2 amino acid residues.
FIG. 15b shows the comparative amino acid sequence of the
Tier 2 amino acid residues (SEQ ID NO.: 8).
FIG. 16 is a sequence alignment of the amino acid
sequence of TEAS active site compared to the amino acid
sequence of the CVS active site. The alignment maximizes
residue similarities and introduce gaps where necessary.
Absolute amino acid numbering is shown for CVS, thus
amino acid numbering from SEQ ID NO.: 4 is shown for
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In accordance with the present invention and as used
herein, the following terms and abbreviations are defined
with the following meanings, unless explicitly stated otherwise. These explanations are intended to be exemplary only.
They are not intended to limit the terms as they are described
or referred to throughout the specification. Rather, these
explanations are meant to include any additional aspects
and/or examples of the terms as described and claimed
herein.
The following abbreviations are used herein:
As used herein, a "derivative" is any compound obtained
from a known or hypothetical compound and containing
essential elements of the parent substance.
The phrase "substantially identical" means that a relevant
sequence is at least 70%, 75%, 80%, 85%, 90%, 92%, 95%
96%, 97%, 98%, or 99% identical to a given sequence. By
way of example, such sequences may be allelic variants,
sequences derived from various species, or they may be
derived from the given sequence by truncation, deletion,
amino acid substitution or addition. Percent identity between
two sequences is determined by standard alignment algorithms such as ClustalX when the two sequences are in best
alignment according to the alignment algorithm.
As used herein, the term "hybridization" or "hybridizes"
under certain conditions is intended to describe conditions
for hybridization and washes under which nucleotide
sequences that are significantly identical or homologous to
each other remain bound to each other. Appropriate hybridization conditions can be selected by those skilled in the art
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with minimal experimentation as exemplified in Ausubel, F.
A.; eta!., eds., Current Protocols in Molecular Biology Vol.
2, John Wiley and Sons, Inc., New York (1995). Additionally, stringency conditions are described in Sambrook et a!.
Molecular Cloning: A Laboratory Manual, 2nd ed., Cold
Spring Harbor Laboratory Press, New York (1989). Variations on the conditions for low, moderate, and high stringency are well known in the art and may be used with the
current invention.
The terms "nucleic acid" or "nucleic acid molecule" refer
to a deoxyribonucleotide or ribonucleotide polymer in either
single- or double-stranded form, and unless otherwise limited, would encompass known analogs of natural nucleotides
that can function in a similar marmer as naturally occurring
nucleotides. A "nucleotide sequence" also refers to a polynucleotide molecule or oligonucleotide molecule in the form
of a separate fragment or as a component of a larger nucleic
acid. The nucleotide sequence or molecule may also be
referred to as a "nucleotide probe." Some of the nucleic acid
molecules of the invention are derived from DNA or RNA
isolated at least once in substantially pure form and in a
quantity or concentration enabling identification, manipulation, and recovery of its component nucleotide sequence by
standard biochemical methods. Examples of such methods,
including methods for PCR protocols that may be used
herein, are disclosed in Sambrook et a!. Molecular Cloning:
A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York (1989), Ausubel, F. A., eta!., eds.,
Current Protocols in Molecular Biology, John Wiley and
Sons, Inc., New York (1987), and Innis, M., eta!. (Eds.) PCR
Protocols: A Guide to Methods and Applications, Academic
Press, San Diego, Calif. (1990). Reference to a nucleic acid
molecule also includes its complement as determined by the
standard Watson-Crick base-pairing rules, with uracil (U) in
RNA replacing thymine (T) in DNA, unless the complement
is specifically excluded.
As described herein, the nucleic acid molecules of the
invention include DNA in both single-stranded and doublestranded form, as well as the DNA or RNA complement
thereof. DNA includes, for example, DNA, genomic DNA,
chemically synthesized DNA, DNA amplified by PCR, and
combinations thereof. Genomic DNA, including translated,
non-translated and control regions, may be isolated by
conventional techniques, e.g., using any one of the cDNAs
of the invention, or suitable fragments thereof, as a probe, to
identify a piece of genomic DNA which can then be cloned
using methods commonly known in the art.
Polypeptides encoded by the nucleic acids of the invention are encompassed by the invention. As used herein,
reference to a nucleic acid "encoding" a protein or polypeptide encompasses not only cDNAs and other intronless
nucleic acids, but also DNAs, such as genomic DNA, with
introns, on the assumption that the introns included have
appropriate splice donor and acceptor sites that will ensure
that the introns are spliced out of the corresponding transcript when the transcript is processed in a eukaryotic cell.
Due to the degeneracy of the genetic code wherein more
than one codon can encode the same amino acid, multiple
DNA sequences can code for the same polypeptide. Such
variant DNA sequences can result from genetic drift or
artificial manipulation (e.g., occurring during PCR amplification or as the product of deliberate mutagenesis of a native
sequence). Deliberate mutagenesis of a native sequence can
be carried out using numerous techniques well known in the
art. For example, oligonucleotide-directed site-specific
mutagenesis procedures can be employed, particularly
where it is desired to mutate a gene such that predetermined

restriction nucleotides or codons are altered by substitution,
deletion or insertion. Exemplary methods of making such
alterations are disclosed by Walder et a!. (Gene
42:133.1986); Bauer eta!. (Gene 37:73, 1985); Craik (BioTechniques, Jan. 12-19, 1985); Smith eta!. (Genetic Engineering: Principles and Methods, Plenum Press, 1981);
Kuukel (Proc. Nat!. Acad. Sci. USA 82:488, 1985); Kuukel
et a!. (Methods in Enzymol. 154.367, 1987). The present
invention thus encompasses any nucleic acid capable of
encoding a protein of the current invention.
The current invention provides for isolated polypeptides.
As used herein, the term "polypeptides" refers to a genus of
polypeptide or peptide fragments that encompass the amino
acid sequences identified herein, as well as smaller fragments. Alternatively, a polypeptide may be defined in terms
of its antigenic relatedness to any peptide encoded by the
nucleic acid sequences of the invention. Thus, in one
embodiment, a polypeptide within the scope of the invention
is defined as an amino acid sequence comprising a linear or
3-dimensional epitope shared with any peptide encoded by
the nucleic acid sequences of the invention. Alternatively, a
polypeptide within the scope of the invention is recognized
by an antibody that specifically recognizes any peptide
encoded by the nucleic acid sequences of the invention.
Antibodies are defined to be specifically binding if they bind
polypeptides of the invention with a Ka of greater than or
equal to about 107 M-I, such as greater than or equal to 10 8
M- 1 . As used herein, the term "isolated," in reference to
polypeptides or proteins, means that the polypeptide or
protein is substantially removed from polypeptides, proteins, nucleic acids, or other macromolecules with which it,
or its analogues, occurs in nature. Although the term "isolated" is not intended to require a specific degree of purity,
typically, the protein will be at least about 75% pure, more
typically at least about 90% pure, preferably at least about
95% pure, and more preferably at least about 99% pure.
A polypeptide "variant" as referred to herein means a
polypeptide substantially homologous to a native polypeptide, but which has an amino acid sequence different from
that encoded by any of the nucleic acid sequences of the
invention because of one or more deletions, insertions or
substitutions. Variants can comprise conservatively substituted sequences, meaning that a given amino acid residue is
replaced by a residue having similar physiochemical characteristics. See Zubay, Biochemistry, Addison-Wesley Pub.
Co., (1983). It is a well-established principle of protein and
peptide chemistry that certain amino acids substitutions,
entitled "conservative" amino acid substitutions, can frequently be made in a protein or a peptide without altering
either the confirmation or the function of the protein or
peptide. Such changes include substituting any of isoleucine
(I), valine (V), and leucine (L) for any other of these amino
acids; aspartic acid (D) for glutamic acid (E) and vice versa;
glutamine (Q) for asparagine (N) and vice versa; and serine
(S) for threonine (T) and vice versa.
The above-mentioned substitutions are not the only amino
acid substitutions that can be considered "conservative."
Other substitutions can also be considered conservative,
depending on the environment of the particular amino acid.
For example, glycine (G) and alanine (A) can frequently be
interchangeable, as can be alanine and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be
interchanged with leucine and isoleucine, and sometimes
with valine. Lysine (K) and arginine (R) are frequently
interchangeable in locations in which the significant feature
of the amino acid residue is its charge and the differing pK's
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of these two amino acid residues are not significant. Still
other changes can be considered "conservative" in particular
environments.
The effects of such substitutions can be calculated using
substitution score matrices such PAM120, PAM-200, and
PAM-250 as discussed in Altschul, (J. Mol. Bioi. 219:55565
(1991)). Other such conservative substitutions, for example,
substitutions of entire regions having similar hydrophobicity
characteristics, are well known.
Naturally-occurring peptide variants are also encompassed by the invention. Examples of such variants are
proteins that result from alternate mRNA splicing events or
from proteolytic cleavage of the polypeptides described
herein. Variations attributable to proteolysis include, for
example, differences in theN- or C-termini upon expression
in different types of host cells, due to proteolytic removal of
one or more terminal amino acids from the polypeptides
encoded by the sequences of the invention.
Variants of the valencene synthase of the invention may
be used to attain desired enhanced or reduced enzymatic
activity, modified regiochemistry or stereochemistry, or
altered substrate utilization or product distribution. A variant
or site direct mutant may be made by any methods known in
the art. Variants and derivatives of native polypeptides can
be obtained by isolating naturally-occurring variants, or the
nucleotide sequence of variants, of other or same plant lines
or species, or by artificially progrming mutations of
nucleotide sequences coding for native citrus polypeptides.
In one embodiment, the invention contemplates: vectors
comprising the nucleic acids of the invention. A vector as
used herein includes any recombinant vector including but
not limited to viral vectors, bacteriophages and plasmids.
Expression vectors containing a nucleic acid sequence of
the invention can be prepared using well known methods
and include a eDNA sequence encoding the polypeptide
operably linked to suitable transcriptional or translational
regulatory nucleotide sequences. Examples of regulatory
sequences include transcriptional promoters, operators, or
enhancers, mRNA ribosomal binding sites, and appropriate
sequences which control transcription and translation initiation and termination. Nucleotide sequences are "operably
linked" when the regulatory sequence functionally relates to
the eDNA sequence of the invention. Expression vectors,
regulatory elements and the construction thereof are well
known in the art, and therefore are not limited to those
recited above.
In addition, sequences encoding appropriate signal peptides that are not naturally associated with the polypeptides
of the invention can be incorporated into expression vectors.
For example, a DNA sequence for a signal peptide (secretory) leader can be fused in-frame to a nucleotide sequence
of the invention so that the polypeptide of the invention is
initially translated as a fusion protein comprising the signal
peptide. A signal peptide that is functional in the intended
host cells enhances extracellular secretion of the expressed
polypeptide. The signal peptide can be cleaved from the
polypeptide upon secretion from the cell. In some cases,
signal peptides are cleaved in two or more stages; this is also
within the scope of the invention where appropriate.
Fusions of additional peptide sequences at the amino and
carboxyl terminal ends of the polypeptides of the invention
can be used with the current invention.
In one embodiment, the invention includes a host cell
comprising a nucleic acid of the invention. Another embodiment of the invention is a method of making a recombinant
host cell comprising introducing the vectors of the invention, into a host cell. In a further embodiment, a method of

producing a polypeptide comprising culturing the host cells
of the invention under conditions to produce the polypeptide
is contemplated. In one embodiment the polypeptide is
recovered. The methods of the invention include methods of
making at least one valencene synthase of the invention
comprising culturing a host cell comprising a nucleic acid of
the invention, and recovering the sesquiterpene synthase
accnmulated.
Suitable host cells for expression of polypeptides of the
invention are well known in the art, and include, but are not
limited to, prokaryotes, yeast, higher eukaryotic cells, or
combinations thereof (See for example, Pauwels et a!.
Cloning Vectors: A Laboratory Manual, Elsevier, New York
(1985)). Cell-free translation systems, also well known in
the art, could also be employed to produce the disclosed
polypeptides using RNAs derived from DNA constructs
disclosed herein.
Host cells may be modified by any methods known in the
art for gene transfer including, for example, the use of
delivery devices such as lipids and viral vectors, naked
DNA, electroporation and particle-mediated gene transfer.
In one embodiment, the cDNAs of the invention may be
expressed in such a way as to produce either sense or
antisense RNA. The expression of antisense RNA can be
used to down-modulate the expression of the protein
encoded by the mRNA to which the antisense RNA is
complementary.
A further embodiment of the invention is methods of
making terpenoids and sesquiterpene compounds, for
example, using the nucleotides and polypeptides of the
invention.
As used herein an acyclic pyrophosphate terpene precursor is any acyclic pryrophosphate compound that is a
precursor to the production of at least one terpene including
but not limited to geranyl-pyrophosphate (GPP), farnesyldiphosphate (FPP) and geranylgeranyl-pyrophosphate
(GGPP).
In one embodiment, the distribution of products or the
actual products formed may be altered by varying the pH at
which the synthase contacts the acyclic pyrophosphate terpene precursor.
Also within the practice of the invention is an organism
(e.g., microorganism or plant) that is used to construct a
platform for high level production of a substrate of sesquiterpene synthases (e.g., FPP) and the introduction of a
nucleic acid of the invention into the organism.
Unless otherwise indicated, nucleic acids of the invention
that are DNA encompass both eDNA (DNA reverse transcribed from mRNA and lacking introns) and isolated
genomic DNA (DNA that can contain introns.)
In one embodiment, the nucleic acids of the invention are
used to create other nucleic acids coding for sesquiterpene
synthases. For example, the invention provides for a method
of identifYing a sesquiterpene synthases comprising constructing a DNA library using the nucleic acids of the
invention, screening the library for nucleic acids which
encode for at least one sesquiterpene synthase. The DNA
library using the nucleic acids of the invention may be
constructed by any process known in the art where DNA
sequences are created using the nucleic acids of the invention as a starting point, including but not limited to DNA
suffling. In such a method, the library may be screened for
sesquiterpene synthases using a functional assay to find a
target nucleic acid that encodes a sesquiterpene synthase.
The activity of a sesquiterpene synthase may be analyzed
using, for example, the methods described herein. In one

10

15

20

25

30

35

40

45

50

55

60

65

US 9,534,237 B2
11

12

embodiment, high through put screening is utilized to analyze the activity of the encoded polypeptides.
As used herein a "nucleotide probe" is defined as an
oligonucleotide or polynucleotide capable of binding to a
target nucleic acid of complementary sequence through one
or more types of chemical bonds, through complementary
base pairing, or through hydrogen bond formation.
A "target nucleic acid" herein refers to a nucleic acid to
which the nucleotide probe or molecule can specifically
hybridize. The probe is designed to determine the presence
or absence of the target nucleic acid, and the amount of
target nucleic acid. The target nucleic acid has a sequence
that is significantly complementary to the nucleic acid
sequence of the corresponding probe directed to the target so
that the probe and the target nucleic acid can hybridize.
Preferably, the hybridization conditions are such that hybridization of the probe is specific for the target nucleic acid. As
recognized by one of skill in the art, the probe may also
contain additional nucleic acids or other moieties, such as
labels, which may not specifically hybridize to the target.
The term target nucleic acid may refer to the specific
nucleotide sequence of a larger nucleic acid to which the
probe is directed or to the overall sequence (e.g., gene or
mRNA). One skilled in the art will recognize the full utility
under various conditions.
Other than in the operating example, or where otherwise
indicated, all numbers expressing quantities of ingredients,
reaction conditions, and so forth used in the specification
and claims are to be understood as being modified in all
instances by the term "about." Accordingly, unless indicated
to the contrary, the numerical parameters set forth in the
specification and claims are approximations that may vary
depending upon the desired properties sought to be obtained
by the present invention. At the very least, and not as an
attempt to limit the application of the doctrine of equivalents
to the scope of the claims, each numerical parameter should
be construed in light of the number of significant digits and
ordinary rounding approaches.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are
approximations, the numerical values set forth in the specific
examples are reported as precisely as possible. Any numerical value; however, inherently contains certain errors necessarily resulting from the standard deviation found in their
respective testing measurements.
Hundreds of genes with similarity to terpene synthases are
readily observed in protein sequence or keyword searches of
GenBank with a significant percentage of these currently
annotated as terpene synthase-like. In order to isolate synthase genes coding for enzymes that share catalytic features
in common with tobacco 5-epi-aristolochene synthase
(TEAS) or Hyoscyamus muticus prenmaspirodiene synthase
(HPS) (FIG. 1), Inventors considered possible biosynthetic
routes for all isomeric forms of the eremophilane-type
sesquiterpenes (FIG. 2). ( +)Valencene and its oxygenated
derivative nootkatone (FIG. 3) were readily recognized as
high value natural products isolated from citrus used as
flavor enhancers. To identifY the terpene synthase responsible for the biosynthesis of valencene, Inventors screened
sequences from several citrus (Citrusxparadisi and Citrus
junos) EST sequencing projects deposited in GenBank (www.ncbi.nlm.nih.gov/Genbank/index.html) for sequences
similar to TEAS and HPS. Two sequences were observed,
one from Citrus junos (accession AF288465) and the other
from Curtis paradisi (accession AF411120). The predicted
proteins from both of these cDNAs were between about 40%
identical and about 60% similar to TEAS, but the C. junos

eDNA predicted a protein that was missing segments of 10
and 12 amino acids relative to TEAS. The isolated protein
from Citrus paradisi was 45% homologous with TEAS (see
below). Inventors, therefore, focused on the isolation and
characterization of a full-length eDNA corresponding to
AF411120 from grapefruit (C. paradisi).
The eDNA isolated by Inventors is a terpene synthase
gene, the protein product of which is citrus valencene
synthase (CVS). The following non-limiting examples
describe Inventors isolation, and expression of the CVS
gene, and also further characterize the CVS protein via
enzyme activity assays and pH assays. Applicants have
further characterized the key amino acid residues comprising the active domain of the CVS protein via these enzyme
activity assays and via a comparison to other eremophilanetype sesquiterpenes, in particular TEAS, HPS and deltacadinene synthase from cotton.
Sequence comparisons between terpene synthases have
suggested that simple sequence alignments are not sufficient
to identifY amino acids or protein regions contributing to
catalytic specificity. Inventors aligned the residues forming
the active region of the isolated CVS with the residues
forming active region of TEAS. In order to perform a
comparative analysis of the two active regions (CVS and
TEAS), the absolute amino acid number for CVS was
shifted to correspond with the TEAS amino acid numbers.
FIG. 16 illustrates the alignment ofCVS amino acid residues
with those of TEAS and maintains the numbering of TEAS
and the numbering for CVS. Inventors then adjusted the
amino acid numbering of CVS to match that of TEAS
(comparative numbering). Tier 1 and Tier 2 amino acid
numbering follows this comparative numbering, thus, Tier 1
and Tier 2 amino acids would also have the comparative
numbering shift (SEQ ID NOS.: 7 and 8, respectively). FIG.
17. Thus, as is used herein the term "absolute numbering"
refers to the sequence number of the CVS amino acid
residues in SEQ ID NO.: 1 and the nucleotide numbering in
SEQ ID NO.: 4. As used herein, the term "comparative
numbering" refers to the sequence numbering of the amino
acid residues based on the TEAS numbering, which were
designated as a means to compare TEAS and CVS active site
amino acid residues, and neighboring residues (Tiers 1 and
2). Nucleic acid residues coding for the amino acids comprising Tier 1 (SEQ ID NO.: 5) and Tier 2 (SEQ ID NO.: 6)
are based on the nucleotide sequence of SEQ ID NO.: 1, and
are absolute numbers.
As is seen in FIG. 4 and FIG. 11 wherein Inventors
compared the amino acids of TEAS, HPS and CVS, only a
single amino acid difference was observed within the 1st tier
residues of TEAS and CVS; however 8 amino acid differences were observed within the second tier residues of
TEAS and CVS. CVS exhibits an alanine at position 403
rather than a threonine as is found in TEAS. Using this
discovery, Inventors have further compared amino acid
residues surrounding the active site and discovered that
these amino acids, termed Tier 2 amino acids and discussed
below, influence the catalytic outcome of these enzymes.
For clarity in this disclosure, Tier 1 amino acids are the
amino acid residues that form the catalytic pocket in a
sesquiterpene synthase, and Tier 2 amino acids are those
amino acids that are within a few angstroms of the Tier 1
residues, preferably between the range of about 1 angstrom
and about 5 angstroms, more preferably between the range
of about 2 angstrom and about 4 angstrom and most preferably 3 angstrom. In this disclosure, the amino acid residue
sequence for Tier 1 and Tier 2, based on the amino acid
residue sequence of SEQ ID NO.: 4, but adjusted for a
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comparative analysis with TEAS, are SEQ ID NO.: 7, shown
in FIG. 14b, and SEQ ID NO.: 8, shown in FIG. 15b. The
corresponding nucleotide sequence for the Tier 1 and Tier 2
amino acid residues, therefore, are based on the nucleotide
sequence of SEQ ID NO.: 1, and are SEQ ID NO.: 5, shown
in FIG. 12, and SEQ ID NO.: 6, shown in FIG. 13. The
recited amino acid residue sequences, recited position number, corresponding nucleotide and nucleotide position number are based on the full protein and nucleotide sequences
recited in SEQ ID NO. 1 and SEQ ID NO.: 4, respectively.
Because the current invention accounts for frame shift
mutations, fusion proteins, fragments, degeneracy of the
genetic code and other events that can change these recited
sequences and positions without loosing the spirit of the
current invention, the sequences and positions of these
events are included in the current invention.
Inventors then analyzed the second tier amino acid residues for the TEAS and CVS protein sequences. Second tier
residues, those amino acid R groups within a few A of the
1st tier amino acids, were examined for differences between
TEAS and CVS (FIG. 4). Three positions within the 2nd tier
exhibited common differences between TEAS and CVS
(positions 402, 436 and 516), as well as substitutions unique
to CVS (270, 401, 407, 448, 515) relative to TEAS. A role
for 2nd tier residues in catalysis, then, includes determining
whether a synthase produces a C7 -C8 double bond or a
C6-C7 double bond. This arises because the final proton
abstraction occurred at C6 rather than C8, a spatial distance
of 3-4 A or approximately the diameter of a methyl group.
Equally important, regia-specific abstraction necessarily
arises from proper geometric positioning of C8 or C6 of the
eremophylyl cation in proximity to an active site residue or
activated water molecule capable of the final abstraction.
Positioning of the final reaction intermediate therefore
comes about by simple spatial allowances created by the
presence or absence of slightly bulkier R -groups on one side
of the active site pocket balanced by the converse on the
opposite site of the pocket. For instance, the poly-threonine
sequence at positions 401-403 of TEAS is replaced by the
small amino acids serine, cysteine and alanine in CVS,
which appear balanced by a smaller amino acid (valine 516)
on the opposite side of the active site pocket in TEAS and
the larger amino acid isoleucine in CVS. Without being
bound by any theory, differences between sesquiterpene
synthases, particularly TEAS and CVS may be due to
alterations of the active site architecture affecting the proton
donor positioning for proton donation; and/or a dynamic
mechanism wherein the intermediate compounds are
brought into proper stereoelectronic aligmnent for the proton
donation and cyclization geometry.
There now follows a description of the isolation, cloning,
sequencing and functional characterization of citrus valencene synthase from Citrus paradisi. These examples are
provided for the purpose of illustrating the invention, and are
not to be considered as limiting.
Accordingly, one aspect of the present invention is an
isolated nucleic acid comprising the nucleic acid sequence
of SEQ ID NO 1. The nucleic acid is typically DNA, but can
be RNA. If it is DNA, it is typically double-stranded, but can
alternatively be single-stranded. Alternatively, it can be an
RNA-DNA hybrid, i.e., either a complete or partial hybrid.
Another aspect of the present invention is an isolated
nucleic acid that encodes the amino acid sequence of SEQ
ID NO: 4. The nucleic acid is typically DNA, but can be
RNA. If it is DNA, it is typically double-stranded, but can
alternatively be single-stranded. Alternatively, it can be an
RNA-DNA hybrid, i.e., either a complete or partial hybrid.

Another aspect of the present invention is an isolated
nucleic acid encoding a protein that has the amino acid
sequence of SEQ ID NO. 4 with 0 to 20 conservative amino
acid substitutions, with the proviso that a conservative
amino acid substitution is not made at amino acids 264, 273,
403, 404, 440, 444, 520, 527, and 528 in the protein that has
the amino acid sequence of SEQ ID NO: 4, wherein the
encoded protein specifically binds farnesyl pyrophosphate in
a substantially hydrophobic pocket and has sesquiterpene
synthase activity. Conservative amino acid substitutions are
defined as above. Preferably, the nucleic acid sequence
encodes a protein with 0 to 10 conservative amino acid
substitutions. More preferably, the nucleic acid sequence
encodes a protein with 0 to 5 conservative amino acid
substitutions. Typically, the nucleic acid is DNA.
Yet another aspect of the present invention is an isolated
nucleic acid encoding a protein that has the amino acid
sequence of SEQ ID NO. 4 with 0 to 20 conservative amino
acid substitutions, with the proviso that a conservative
amino acid substitution is not made at amino acids 20, 264,
266,270,273,298,302,372,376,401,402,403,404,407,
436,440,441,444,445,448,512,515,516,519,520,527,
528, and 529 in the protein that has the amino acid sequence
of SEQ ID NO: 4, wherein the encoded protein specifically
binds farnesyl pyrophosphate in a substantially hydrophobic
pocket and has sesquiterpene synthase activity. Preferably,
the nucleic acid sequence encodes a protein with 0 to 10
conservative amino acid substitutions. More preferably, the
nucleic acid sequence encodes a protein with 0 to 5 conservative amino acid substitutions. Typically, the nucleic acid is
DNA.
Yet another aspect of the invention is an isolated nucleic
acid that hybridizes to the nucleic acid of SEQ ID NO: 1
under stringent conditions with no more than about a 5%
mismatch. Preferably, there is no more than about a 2%
mismatch. More preferably, there is no more than about a
1% mismatch. Typically, the nucleic acid is DNA.
Yet another aspect of the invention is an isolated nucleic
acid that encodes a protein that is at least 500 amino acids
in length, that specifically binds farnesyl pyrophosphate in a
hydrophobic pocket, and that has sesquiterpene synthase
activity, wherein the nucleic acid includes SEQ ID NO. 5
and SEQ ID NO. 6. Typically, the nucleic acid is DNA.
Still another aspect of the invention is an isolated nucleic
acid that encodes a protein that is at least 500 amino acids
in length, that specifically binds farnesyl pyrophosphate in a
hydrophobic pocket, and that has sesquiterpene synthase
activity, wherein the nucleic acid includes SEQ ID NO. 5.
Typically, the nucleic acid is DNA.
Still another aspect of the invention is an isolated nucleic
acid that encodes a protein that includes amino acid residues
264 to 528 of SEQ ID NO. 4, wherein the protein specifically binds farnesyl pyrophosphate in a hydrophobic pocket
and has sesquiterpene synthase activity. Typically, the
nucleic acid is DNA.
As defined above, another embodiment of the invention is
an isolated polypeptide having appropriate enzymatic activity, namely sesquiterpene synthase activity. These isolated
polypeptides include, but are not necessary limited to:
(1) the polypeptide of SEQ ID NO: 4;
(2) a polypeptide that has the amino acid sequence of SEQ
ID NO. 4 with 0 to 20 conservative amino acid substitutions, with the proviso that a conservative amino
acid substitution is not made at amino acids 264, 273,
403, 404, 440, 444, 520, 527, and 528 in the protein that
has the amino acid sequence of SEQ ID NO: 4, wherein
the encoded protein specifically binds farnesyl pyro-
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phosphate in a substantially hydrophobic pocket and
has sesquiterpene synthase activity, preferably with 0 to
10 conservative amino acid substitutions, more preferably with 0 to 5 conservative amino acid substitutions;
(3) a polypeptide that has the amino acid sequence of SEQ
ID NO. 4 with 0 to 20 conservative amino acid substitutions, with the proviso that a conservative amino
acid substitution is not made at amino acids 20, 264,
266,270,273,298,302,372,376,401,402,403,404,
407,436,440,441,444,445,448,512,515,516,519,
520, 527, 528, and 529 in the protein that has the amino
acid sequence of SEQ ID NO: 4, wherein the encoded
protein specifically binds farnesyl pyrophosphate in a
substantially hydrophobic pocket and has sesquiterpene
synthase activity, preferably with 0 to 10 conservative
amino acid substitutions, more preferably with 0 to 5
conservative amino acid substitutions;
(4) a polypeptide encoded by an isolated nucleic acid that
hybridizes to the nucleic acid of SEQ ID NO: 1 under
stringent conditions with no more than about a 5%
mismatch, preferably no more than about a 2% mismatch, more preferably no more than about a 1%
mismatch;
(5) a polypeptide that is at least 500 amino acids in length,
that specifically binds farnesyl pyrophosphate in a
hydrophobic pocket, and that has sesquiterpene synthase activity, wherein the sequence of the protein
includes SEQ ID NO. 7 and SEQ ID NO. 8;
(6) a polypeptide that is at least 500 amino acids in length,
that specifically binds farnesyl pyrophosphate in a
hydrophobic pocket, and that has sesquiterpene synthase activity, wherein the sequence of the protein
includes SEQ ID NO.7; and
(7) a polypeptide that includes amino acid residues 264 to
528 of SEQ ID NO. 4, wherein the protein specifically
binds farnesyl pyrophosphate in a hydrophobic pocket
and has sesquiterpene synthase activity.
Typically, the sesquiterpene synthase activity of proteins
or polypeptides within the scope of the present invention is
valencene synthase activity, but other sesquiterpenes can be
synthesized by proteins or polypeptides within the scope of
the present invention, either as the major reaction product or
in side reactions.
Another embodiment of the present invention is a vector
comprising a nucleic acid of the present invention, as
described above, operably linked to at least one control
sequence. Typically, the control sequence is a promoter or
enhancer. As described above, such vectors are well known
in the art.
Yet another embodiment of the present invention is a host
cell transformed or transfected with a vector of the present
invention. The host cell can be a prokaryotic cell or a
eukaryotic cell, such as a bacterial cell, a yeast cell, a plant
cell, or an animal cell, such as an insect cell or a mammalian
cell. Typically, the host cell transformed or transfected with
the vector is capable of expressing the protein or polypeptide
encoded by the vector. Suitable host cells for expression of
polypeptides of the invention include prokaryotes, yeast or
higher eukaryotic cells. Appropriate cloning and expression
vectors for use with bacterial, fungal, yeast, and mmalian
cellular hosts are described, for example, in Pauwels et a!.,
Cloning Vectors. A Laboratory Manual, Elsevier, New York,
(1985). Cell-free translation systems could also be employed
to produce the disclosed polypeptides using RNAs derived
from DNA constructs disclosed herein.
Prokaryotes include gram negative or grain positive
organisms, for example, E. coli or Bacilli. Suitable prokary-

otic host cells for transformation include, for example, E.
coli, Bacillus subtilis, Salmonella typhimurium, and various
other species within the genera Pseudomonas, Streptomyces,
and Staphylococcus. In a prokaryotic host cell, such as E.
coli, the polypeptides can include aN-terminal methionine
residue to facilitate expression of the 16 recombinant polypeptide in the prokaryotic host cell. TheN-terminal methionine can be cleaved from the expressed recombinant polypeptide.
Examples of useful expression vectors for prokaryotic
host cells include those derived from commercially available
plasmids such as the cloning vector pET plasmids (Novagen,
Madison, Wis., USA) or yet pBR322 (ATCC 37017).
pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. To construct an expression vector using
pBR322, an appropriate promoter and a DNA sequence
encoding one or more of the polypeptides of the invention
are inserted into the pBR322 vector. Other commercially
available vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM-1 (Promega Biotec, Madison, Wis., USA). Other commercially
available vectors include those that are specifically designed
for the expression of proteins; these would include pMALp2 and pMAL-c2 vectors that are used for the expression of
proteins fused to maltose binding protein (New England
Biolabs, Beverly, Mass., USA).
Promoter sequences commonly used for recombinant
prokaryotic host cell expression vectors include bacteriophage T7 promoter (Studier F. W. and Moffatt B. A., J. Mol.
Bioi. 189:113, 1986), ~-lactamase (penicillinase), lactose
promoter system (Chang eta!., Nature 275:615, 1978; and
Goedde! et a!., Nature 281:544, 1979), tryptophan (trp)
promoter system (Goedde! et a!., Nucl. Acids Res. 8:4057,
19.80; and EP-A-36776), and tac promoter (Maniatis,
Molecular Cloning: A Laboratory Manual, Cold Spring
Harbor Laboratory, p. 412. 1982). A particularly useful
prokaryotic host cell expression system employs a phage A
PL promoter and a c1857ts thermolabile repressor sequence.
Plasmid vectors available from the American Type Culture
Collection ("ATCC"), which incorporate derivatives of the
PL promoter, include plasmid pHUB2 (resident in E. coli
strain JMB9 (ATCC 37092)) and pPLc28 (resident in E. coli
RR1 (ATCC 53082)).
Polypeptides of the invention can also be expressed in
yeast host cells, preferably from the Saccharomyces genus
(e.g., S. cerevisiae). Other genera of yeast, such as Pichia or
Kluyveromyces (e.g. K. lactis), can also be employed. Yeast
vectors will often contain an origin of replication sequence
from a 2fl yeast plasmid, an autonomously replicating
sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a
selectable marker gene. Suitable promoter sequences for
yeast vectors include, among others, promoters for metallothionine, 3-phosphoglycerate kinase (Hitzeman et a!., J.
Bioi. Chern. 255:2073, 1980), or other glycolytic enzymes
(Hess eta!., J. Adv. Enzyme Reg. 7:149, 1968; and Holland
eta!., Biochem. 17:4900, 1978), such as enolase, glyceraldehyde phosphate dehydrogenase, hexokinase, pyruvate
decarboxylase, phosphofructokinase, glucose phosphate
isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and
glucokinase. Other suitable vectors and promoters for use in
yeast expression are further described in Hitzeman, EPA73,657 or in Fleer et. a!., Gene, 107:285-195 (1991); and van
den Berget. a!., Bio/Technology, 8:135-139 (1990). Another
alternative is the glucose-repressible ADH2 promoter
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described by Russell eta!. (J. Bioi. Chern. 258:2674, 1982)
and Beier et a!. (Nature 300:724, 1982). Shuttle vectors
replicable in both yeast and E. coli can be constructed by
inserting DNA sequences from pBR322 for selection and
replication in E. coli (Ampr gene and origin of replication)
into the above-described yeast vectors.
In one embodiment, mammalian or insect host cell culture
systems are employed to express recombinant polypeptides
of the invention. Baculovirus systems for production of
heterologous proteins in insect cells are reviewed by
Luckow and Surmners, BioTechnology 6:47 (1988). Established cell lines of mammalian origin also can be employed.
Examples of suitable mmalian host cell lines include the
COS-7 line of monkey kidney cells (ATCC CRL 1651)
(Gluzman eta!., Cell23:175, 1981), L cells, C1 27 cells, 3T3
cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells,
HeLa cells, and BHK (ATCC CRL 10) cell lines, and the
CV-1/EBNA-1 cell line (ATCC CRL 10478) derived from
the African green monkey kidney cell line CV1 (ATCC CCL
70) as described by McMahan eta!. (EMBO J. 10: 2821,
1991 ).
In one embodiment, transfected DNA is integrated into a
chromosome of a non-human organism such that a stable
recombinant system results. Any chromosomal integration
method known in the art may be used in the practice of the
invention, including but not limited to, recombinase-mediated cassette exchange (RMCE), viral site specific chromosomal insertion, adenovirus, and pronuclear injection.
Yet another embodiment of the present invention is a
non-human multicellular organism that is modified to harbor
a nucleic acid of the present invention such that the nucleic
acid can be expressed in the non-human multicellular organism. The non-human multicellular organism can be, but is
not necessarily limited to, a plant or insect. The plant can be
the tobacco plant. The non-human organism can be modified
by any of the methods known in the art for gene transfer and
the production of transgenic organisms, including, but not
necessarily limited to, the use of delivery devices such as
lipids and viral vectors, naked DNA, electroporation, and
particle-mediated gene transfer.
Established methods for introducing DNA into mammalian cells have been described (Kaufman, R. J., Large Scale
Mammalian Cell Culture, 1990, pp. 15-69). Additional protocols using commercially available reagents, such as Lipofectamine (Gibco/BRL) or Lipofectamine-Plus, can be used
to transfect cells (Feigner et a!., Proc. Nat!. Acad. Sci. USA
84:7413-7417, 1987). In addition, electroporation can be
used to transfect mammalian cells using conventional procedures, such as those in Sambrook et a!. Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1-3, Cold Spring
Harbor Laboratory Press, 1989). Selection of stable transformants can be performed using resistance to cytotoxic
drugs as a selection method. Kaufman et a!., Meth. in
Enzymology 185:487-511, 1990, describes several selection
schemes, such as dihydrofolate reductase (DHFR) resistance. A suitable host strain for DHFR selection can be CHO
strain DX-131 1, which is deficient in DHFR (Urlaub and
Chasin, Proc. Nat!. Acad. Sci. USA 77:4216-4220, 1980). A
plasmid expressing the DHFR eDNA can be introduced into
strain DX-131 1, and only cells that contain the plasmid can
grow in the appropriate selective media.
Transcriptional and translational control sequences for
mammalian host cell expression vectors can be excised from
viral genomes. Commonly used promoter sequences and
enhancer sequences are derived from polyoma virus, adenavirus 2, simian virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome,

for example, SV40 origin, early and later promoter,
enhancer, splice, and polyadenylation sites can be used to
provide other genetic elements for expression of a structural
gene sequence in a mmalian host cell. Viral early and late
promoters are particularly useful because both are easily
obtained from a viral genome as a fragment, which can also
contain a viral origin of replication (Piers et a!., Nature
273:113, 1978; Kaufman, Meth. in Enzymology, 1990).
There are several methods known in the art for the
creation of transgenic plants. These include, but are not
limited to: electroporation of plant protoplasts, liposomemediated transformation, polyethylene-glycol-mediated
transformation, microinjection of plant cells, and transformation using viruses. In one embodiment, direct gene transfer by particle bombardment is utilized.
Direct gene transfer by particle bombardment provides an
example for transforming plant tissue. In this technique a
particle, or microprojectile, coated with DNA is shot through
the physical barriers of the cell. Particle bombardment can
be used to introduce DNA into any target tissue that is
penetrable by DNA coated particles, but for stable transformation, it is imperative that regenerable cells be used.
Typically, the particles are made of gold or tungsten. The
particles are coated with DNA using either CaCI 2 or ethanol
precipitation methods which are commonly known in the
art.
DNA coated particles are shot out of a particle gun. A
suitable particle gun can be purchased from Bio-Rad Laboratories (Hercules, Calif.). Particle penetration is controlled
by varying parameters such as the intensity of the explosive
burst, the size of the particles, or the distance particles must
travel to reach the target tissue.
The DNA used for coating the particles may comprise an
expression cassette suitable for driving the expression of the
gene of interest that will comprise a promoter operably
linked to the gene of interest.
Methods for performing direct gene transfer by particle
bombardment are disclosed in U.S. Pat. No. 5,990,387 to
Tomes et a!., incorporated herein by this reference.
In one embodiment, the cDNAs of the invention may be
expressed in such a way as to produce either sense or
antisense RNA. Antisense RNA is RNA that has a sequence
which is the reverse complement of the mRNA (sense RNA)
encoded by a gene. A vector that will drive the expression of
antisense RNA is one in which the ONA is placed in "reverse
orientation" with respect to the promoter such that the
non-coding strand (rather than the coding strand) is transcribed. The expression of antisense RNA can be used to
down-modulate the expression of the protein encoded by the
mRNA to which the antisense RNA is complementary.
Vectors producing antisense RNAs could be used to make
transgenic plants, as described above.
In one embodiment, transfected DNA is integrated into a
chromosome of a non-human organism such that a stable
recombinant systems results. Any chromosomal integration
method known in the art may be used in the practice of the
invention, including but not limited to, recombinase-mediated cassette exchange (RMCE), viral site specific chromosomal insertion, adenovirus, and pronuclear injection.
Still another embodiment of the invention is a method of
producing a sesquiterpene synthase comprising the steps of:
(1) culturing a host cell transformed or transfected by a
vector of the present invention under conditions in
which the sesquiterpene synthase encoded by the vector
is expressed; and
(2) isolating the sesquiterpene synthase expressed by the
host cell.
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Typically, the sesquiterpene synthase is valencene synan aliquot of the first strand eDNA using standard PCR
conditions. An amplification fragment approximating the
thase, as described above.
expected size of 1,800 bp was observed by agarose gel
Yet another embodiment of the invention is a method of
electrophoresis, T/A cloned into the pGem T-easy vector
producing a sesquiterpene comprising the steps of:
(1) reacting a protein or polypeptide of the present inven- 5 (Promega, Madison, Wis.) and then subjected to automated
DNA sequencing using the BigDye terminator system with
tion having sesquiterpene synthase enzymatic activity
an ABI 310 sequencer. The sequence, which is shown in
with famesyl pyrophosphate under conditions in which
FIG. 5, was obtained from start to stop codons in duplicate
the enzymatic activity catalyzes the formation of a
and rectified with the reported sequence for the Citrusx
sesquiterpene; and
10 paradisi putative terpene synthase mRNA. (Seq ID: 1). One
(2) isolating the sesquiterpene formed in step (1).
nucleotide was found to be altered in the recovered eDNA,
Typically, the sesquiterpene synthase is a valencene syn1544 bp 5' to the ATG start site an A instead of a G was
thase, in which case the sesquiterpene formed is valencene.
observed, converting codon 492 from specifYing an asparStill another embodiment of the present invention is a
tate to an arginine. Sequence analysis was performed using
method of producing nootkatone. In one alternative of this
15 software tools available from the NCBI web site (wwembodiment, the method comprises the steps of:
w.ncbi.nlm.nih.gov) or using ClustalX.
(1) reacting a protein or polypeptide of the present invention having valencene synthase enzymatic activity with
Example 2
famesyl pyrophosphate under conditions in which the
enzymatic activity catalyzes the formation of valen20
Expression of Citrus Valencene Synthase in E. coli
cene;
(2) reacting the valencene formed in step (1) by regiaThe Citrus valencene synthase (CVS) eDNA was inserted
specific hydroxylation and then oxidation to form nootinto an appropriate expression vector, pGEM to provide an
katone; and
amino-terminal hexa-histidyl tag for protein purification
(3) isolating the nootkatone produced.
The second step could be catalyzed by a single multi- 25 after expression of the putative valencene synthase eDNA in
E. coli. The eDNA was re-amplified using PCR primers
functional hydroxylase or could be catalyzed by sequential
designed to amplify from the ATG start codon (5'enzyme mediated reactions.
GGGGAATTCATCTGGTCTGGAGAAACATTTCGTCCYet another embodiment of the invention is an antisense
3'
(SEQ ID NO.: 2) to the TGA stop codon (5'-CCGCTCnucleic acid that is the complement of a nucleic acid
30 GAGGAAGTATAGAACTAGTCGTCAAAATGG-3' (SEQ
according to the present invention as described above.
ID N0.:3)) and to provide restriction sites EcoRI and Xhoi,
(NEB, Beverly Mass.) respectively, using the pGEM-CVS
EXAMPLES
plasmid as template under standard PCR conditions. The
PCR product was digested with EcoRI and Xhoi, purified
A eDNA of 1710 bp was prepared from fresh grapefruit
via RT-PCR using non-degenerate primers designed to 35 using a QIAquick PCR purification kit (Qiagen, Valencia,
Calif.), and ligated into a pET-28a(+) expression vector
amplify from the translation stall to, stop sites of AF411120,
(Novagen, San Diego, Calif.) that had been digested with
then inserted into appropriate vectors for DNA sequencing
corresponding enzymes (NEB, Beverly Mass.), dephosphoand bacterial expression. For enzymological studies, the
rylated with calf intestine alkaline phosphatase (Invitrogen,
eDNA was inserted into a pET expression vector in-frame
with an amino terminal hexa-histidine tag, and lysates of 40 Carlsbad, Calif.), and purified with a QIAquick kit. Proper
construction of the resulting expression vector was verified
appropriately grown bacterial cultures used for nickel-affinby DNA sequencing and subsequently referred to as the
ity purification of the citrus eDNA encoded protein. The
pET-28a( +)-CVS expression vector. The expression vector
isolated citrus protein was approximately 30-40% pure as
was transformed into BL21 (DE3) cells (Stratagene, La
determined by Coomassie blue staining after SDS-PAGE
and migrated as a 64 kD polypeptide (data not shown). The 45 Jolla, Calif.), and grown in a 10 mL inoculate ofLB Growth
Media, using well known techniques. The cells were grown
conceptual translation of the isolated eDNA predicted a
to an OD 600 =1. IPTG (Sigma-Aldrich, St. Louis, Mo.) was
protein of 548 amino acids having a molecular size of
used to induce expression of the putative valencene synthase
63,646 daltons.
gene. The transformed cells were incubated at 28° C. for
Example 1
50 four hours, centrifuged to form a pellet and the pellet was
collected and resuspended in 1 mL of cyclase buffer (200
Molecular Cloning of a Citrus Sesquiterpene
mM Tris-HCl, pH 7.5, 40 mM MgC1 2 ). Cells were then
Synthase eDNA
sonicated with three 10-sec bursts using a microtip ultrasonicator at 40% power and the lysate was centrifuged at
RNA was isolated from the juice vesicles of freshly 55 10,000xg for 10 minutes.
harvested red grapefruit using TRIZOL reagent and followSamples of the lysate were divided and some samples
ing the manufacturer's protocol (Invitrogen Corp., Carlsbad,
were assayed for protein purity, while other samples were
Calif.). Reverse transcription of the isolated RNA also
used in Example 3 below. For the protein purity assay,
followed manufacturer's protocol, and 10 flg of total RNA
protein was purified by nickel affinity chromatography
was reverse transcribed using Superscript II RNase H 60 according to Mathis et a!. (J. R. Mathis, K. Back, C. Starks,
(Strata gene, La Jolla Calif.) and a reverse primer (18 nucleoJ. Noel, C. D. Poulter, J. Chappell, Biochem. 36 (1997)
tides in length) complementary to the 3' end including the
8340-8348). Isolated CVS protein was approximately 30 to
stop codon of the AF 411120 sequence reported in Genbank.
40% pure based on the intensity of Coomassie blue staining
A full-length eDNA was then amplified using Pfu turbo Taq
of samples analyzed by SDS-PAGE. A protein sequencing
polymerase (Stratagene, La Jolla Calif.), more of the initial 65 reaction was performed via the Edman Degradation reaction
reverse primer, a forward primer (18 nucleotides in length)
performed using a Perkin Elmer Applied Biosystems Model
complementary to the 5' end initiating at the start codon, and
494 Procise protein/peptide sequencer with an on-line Per-
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kin Elmer Applied Biosystems Model 140C PTH Amino
Acid Analyzer. The protein sequence for the expressed CVS
protein is shown in FIG. 6. (SEQ ID NO.; 4)
Partially purified protein was subsequently incubated with
FPP at pH 7.5 using typical sesquiterpene synthase reaction
conditions and the pentane extractable products examined
by GC-MS (FIG. 7). Two compounds accounting for greater
than 95% of the total reaction products dominated the GC
profiles and were identified as beta-elemene (30%) and
valencene (65%) on the basis ofMS matches with authentic
standards. The beta-elemene peak most certainly represents
a thermal rearrangement product of germacrene A resulting
from high temperature injection into the GC.

accumulate in citrus fruit suggested that the CVS enzyme
might have a pH optimal different from other terpene
synthases.
As shown in FIG. 10, virtually no germacrene A was
detected as a reaction product between pH 6.0 to 7.0, with
optimal valencene biosynthesis occurring at pH 7.0 (FIG.
10). In contrast, germacrene A biosynthesis was optimal at
pH 8.5 with a relatively sharp transition point from valence
as the dominate reaction product to germacrene A at pH 8.0.

Example 3

10

Example 4
pH Dependence Assays
15

Terpene Synthase Activity Assays and Reaction
Product Identification
20

Small scale reactions of 50 f.LL were used for screening
purposes and rate determinations. Reactions typically contained 200 mM Tris-HCl, pH 7.5, 40 mM MgC1 2 , 0.5 fJ.Ci
[1-3H]FPP, 25-30 f.LM FPP and 160 nM enzyme. For kinetic
determinations, 10 f.LL aliquots of FPP (giving final concentrations of 0.7-23 f.LM) were rapidly mixed with 40 f.LL of
enzyme solution at room temperature (23° C.) and allowed
to incubate for 1 minute. The reactions were terminated by
addition of 150 f.LL, of a 100 mM KOH, 0.5 M EDTA stop
solution. Reactions were extracted with 500 f.LL of hexane
and an aliquot was taken for determination of radiolabeled
hydrophobic product via liquid scintillation counting.
Hexane extracted samples were not subject to silica chromatography prior to counting because background was
minimal and synthase mutants could possibly produce reaction products containing alcohols, which would bind to
silica. Kinetic constants were determined from direct fits of
the Michaelis-Menton equation to the data using Graphpad
Prism 2.01 software.
Initial synthase reaction products were examined by GCMS. Preparative reactions were performed similarly to the
reactions described above except they were scaled to 2.5 mL
and employed 2 f.LM of purified enzyme and 80 f.LM of
unlabeled FPP. The reactions were incubated for 1 hr and
then extracted twice with 2 mL of pentane. Pooled extracts
were dried to 50 f.LL under a stream of nitrogen gas and 1 f.LL
aliquots of this organic extract were analyzed by GC-MS
using an HP-GCDplus (Hewlett-Packard, Palo Alto, Calif.)
equipped with a DB-5 ms colunm, an injector temperature of
250° C. and the mass selective detector set to scan for ions
within the range from 45 to 250 m/z. The GC was programmed to hold for 1 minute at 100° C., followed by a
temperature ramp of8° C./min to a final temperature of270°
C. The results are shown in FIG. 7. Spectra from this
analysis was compared to the NIST library standard for
beta-elemene (FIG. 8) and to that for a sample ofvalencene
purchased from Fluka Chemical Company (FIG. 9).
The dominance of valencene as a reaction product under
these conditions was sufficient to classify the C. paradisi
eDNA as citrus valencene synthase, CVS. However, the
amount of germacrene A, a putative reaction intermediate
(FIG. 1), generated by the CVS enzyme was atypical relative
to previous studies with TEAS and HPS. Neither of these
enzymes release appreciable amounts of reaction intermediates. Further consideration of the acidic conditions likely
to exist within juice vesicles/sacs where sesquiterpenes

25

30

35

40

45

50

55

60

65

Reactions to determine pH dependence were performed in
glass GC-vials with 100 nM of purified enzyme, 20 mM
MgC1 2 , 50 f.LM FPP (Echelon; Salt Lake City, Utah), and 100
mM buffer at various pH values; total reaction volume 500
f.LL. The buffers were chosen within one pH unit of the
buffer's pKa (pH 5-5.5, acetate; pH 6-7, MES; pH 7.5-9,
Tris; pH 9.5-10, ethanolamine; pH 10.5, CAPS). Reactions
were allowed to proceed at room temperature for 30 min
prior to overlaying with 500 f.LL of ethylacetate, vortexing for
10 sec, then direct analysis of the reaction products using an
HP 6890 gas chromatograph with a 5973 mass spectrometer
(Agilent Technologies, Palo Alto, Calif.) with an autosampler programmed to remove 1 samples only from the
organic phase. GC separations were performed on a 5%-phenyl-methylpolysiloxane colunm (J&M Scientific, Folsom,
Calif.) of 30 mx0.25 mm i.d.x0.25 m thickness with He as
the carrier gas at 2 mL/min and a temperature gradient of 1oo
C./min from 50° C. (5-min hold) to 180° C. (4-min hold).
GC/MS data was analyzed using HP-Chemstation software
(version B.01.00) and integration of terpene peaks used for
quantification.
As seen in FIG. 10, a pH dependent transition between
valencene and germacrene A biosynthesis occurs at approximately pH 8.2. Inventors interpreted this as a titration point
for the protonation of germacrene A. This pH value is close
to the pKa value of 8.3-8.5 for free cysteine, which is
involved in the second protonation step of the chemical
cascade catalyzed by TEAS. Those results demonstrated that
when C440 of TEAS was mutated to alanine, a robust
germacrene A synthetic activity resulted. In combination
with the sequence data provided in SEQ ID NO.: 7 and SEQ
ID NO.: 8, it is apparent that germacrene synthases consistently differ from CVS, TEAS and HPS by the absence of
cysteine at position 440 in their putative active site while
Y520, previously implicated in the same protonation step, is
conserved. The observation of germacrene A as a reaction
product and the pH dependence for its synthesis are consistent with its intermediacy in the reaction catalyzed by CVS.
The inventions illustratively described herein can suitably
be practiced in the absence of any element or elements,
limitation or limitations, not specifically disclosed herein.
Thus, for example, the terms "comprising," "including,"
"containing," etc. shall be read expansively and without
limitation. Additionally, the terms and expressions
employed herein have been used as terms of description and
not of limitation, and there is no intention in the use of such
terms and expressions of excluding any equivalents of the
future shown and described or any portion thereof, and it is
recognized that various modifications are possible within the
scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional
features, modification and variation of the inventions herein
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disclosed can be resorted by those skilled in the art, and that
such modifications and variations are considered to be
within the scope of the inventions disclosed herein. The
inventions have been described broadly and generically
herein. Each of the narrower species and sub generic groupings falling within the scope of the generic disclosure also
form part of these inventions. This includes the generic
description of each invention with a proviso or negative
limitation removing any subject matter from the genus,
regardless of whether or not the excised materials specifically resided therein.
In addition, where features or aspects of an invention are
described in terms of the Markush group, those schooled in

the art will recognize that the invention is also thereby
described in terms of any individual member or subgroup of
members of the Markush group. It is also to be understood
that the above description is intended to be illustrative and
not restrictive. Many embodiments will be apparent to those
of in the art upon reviewing the above description. The scope
of the invention should therefore, be determined not with
reference to the above description, but should instead be
determined with reference to the appended claims, along
with the full scope of equivalents to which such claims are
entitled. The disclosures of all articles and references,
including patent publications, are incorporated herein by
reference.

10

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

8

SEQ ID NO 1
LENGTH, 1647
TYPE, DNA
ORGANISM, Citrus X paradisi

<400> SEQUENCE,

1

atgtcgtctg gagaaacatt tcgtcctact gcagatttcc atcctagttt atggagaaac

60

catttcctca aaggtgcttc tgatttcaag acagttgatc atactgcaac tcaagaacga

120

cacgaggcac tgaaagaaga ggtaaggaga atgataacag atgctgaaga taagcctgtt

180

cagaagttac gcttgattga tgaagtacaa cgcctggggg tggcttatca ctttgagaaa

240

gaaatagaag atgcaatact aaaattatgt ccaatctata ttgacagtaa tagagctgat

300

ctccacaccg tttcccttca ttttcgattg cttaggcagc aaggaatcaa gatttcatgt

360

gatgtgtttg agaagttcaa agatgatgag ggtagattca agtcatcgtt gataaacgat

420

gttcaaggga tgttaagttt gtacgaggca gcatacatgg cagttcgcgg agaacatata

480

ttagatgaag ccattgcttt cactaccact cacctgaagt cattggtagc tcaggatcat

540

gtaaccccta agcttgcgga acagataaat catgctttat accgtcctct tcgtaaaacc

600

ctaccaagat tagaggcgag gtattttatg tccatgatca attcaacaag tgatcattta

660

tacaataaaa ctctgctgaa ttttgcaaag ttagatttta acatattgct agagccgcac

720

aaggaggaac tcaatgaatt aacaaagtgg tggaaagatt tagacttcac tacaaaacta

780

ccttatgcaa gagacagatt agtggagtta tatttttggg atttagggac atacttcgag

840

cctcaatatg catttgggag aaagataatg acccaattaa attacatatt atccatcata

900

gatgatactt atgatgcgta tggtacactt gaagaactca gcctctttac tgaagcagtt

960

caaagatgga atattgaggc cgtagatatg cttccagaat acatgaaatt gatttacagg

1020

acactcttag atgcttttaa tgaaattgag gaagatatgg ccaagcaagg aagatcacac

1080

tgcgtacgtt atgcaaaaga ggagaatcaa aaagtaattg gagcatactc tgttcaagcc

1140

aaatggttca gtgaaggtta cgttccaaca attgaggagt atatgcctat tgcactaaca

1200

agttgtgctt acacattcgt cataacaaat tccttccttg gcatgggtga ttttgcaact

1260

aaagaggttt ttgaatggat ctccaataac cctaaggttg taaaagcagc atcagttatc

1320

tgcagactca tggatgacat gcaaggtcat gagtttgagc agaagagagg acatgttgcg

1380

tcagctattg aatgttacac gaagcagcat ggtgtctcta aggaagaggc aattaaaatg

1440

tttgaagaag aagttgcaaa tgcatggaaa gatattaacg aggagttgat gatgaagcca

1500

accgtcgttg cccgaccact gctcgggacg attcttaatc ttgctcgtgc aattgatttt

1560
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-continued

atttacaaag aggacgacgg ctatacgcat tcttacctaa ttaaagatca aattgcttct

1620

gtgctaggag accacgttcc attttga

1647

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 35
TYPE, DNA
ORGANISM, Citrus X paradisi

<400> SEQUENCE, 2
ggggaattca tctggtctgg agaaacattt cgtcc

<210>
<211>
<212>
<213>

35

SEQ ID NO 3
LENGTH, 36
TYPE, DNA
ORGANISM, Citrus X paradisi

<400> SEQUENCE, 3
ccgctcgagg aagtatagaa ctagtcgtca aaatgg

<210>
<211>
<212>
<213>

SEQ ID NO 4
LENGTH, 548
TYPE, PRT
ORGANISM, Citrus X paradisi

<400> SEQUENCE, 4
Met Ser Ser Gly Glu Thr Phe Arg Pro Thr Ala Asp Phe His Pro Ser
1
5
10
15
Leu Trp Arg Asn His Phe Leu Lys Gly Ala Ser Asp Phe Lys Thr Val
20
25
30
Asp His Thr Ala Thr Gln Glu Arg His Glu Ala Leu Lys Glu Glu Val
35
40
45
Arg Arg Met Ile Thr Asp Ala Glu Asp Lys Pro Val Gln Lys Leu Arg
50
55
60
Leu Ile Asp Glu Val Gln Arg Leu Gly Val Ala Tyr His Phe Glu Lys
65
70
75
80
Glu Ile Glu Asp Ala Ile Leu Lys Leu Cys Pro Ile Tyr Ile Asp Ser
85
90
95
Asn Arg Ala Asp Leu His Thr Val Ser Leu His Phe Arg Leu Leu Arg
100
105
110
Gln Gln Gly Ile Lys Ile Ser Cys Asp Val Phe Glu Lys Phe Lys Asp
115
120
125
Asp Glu Gly Arg Phe Lys Ser Ser Leu Ile Asn Asp Val Gln Gly Met
130
135
140
Leu Ser Leu Tyr Glu Ala Ala Tyr Met Ala Val Arg Gly Glu His Ile
145
150
155
160
Leu Asp Glu Ala Ile Ala Phe Thr Thr Thr His Leu Lys Ser Leu Val
165
170
175
Ala Gln Asp His Val Thr Pro Lys Leu Ala Glu Gln Ile Asn His Ala
180
185
190
Leu Tyr Arg Pro Leu Arg Lys Thr Leu Pro Arg Leu Glu Ala Arg Tyr
195
200
205
Phe Met Ser Met Ile Asn Ser Thr Ser Asp His Leu Tyr Asn Lys Thr
210
215
220
Leu Leu Asn Phe Ala Lys Leu Asp Phe Asn Ile Leu Leu Glu Pro His
225
230
235
240
Lys Glu Glu Leu Asn Glu Leu Thr Lys Trp Trp Lys Asp Leu Asp Phe
245
250
255

36
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Thr Thr Lys Leu Pro Tyr Ala Arg Asp Arg Leu Val Glu Leu Tyr Phe
260
265
270
Trp Asp Leu Gly Thr Tyr Phe Glu Pro Gln Tyr Ala Phe Gly Arg Lys
275
280
285
Ile Met Thr Gln Leu Asn Tyr Ile Leu Ser Ile Ile Asp Asp Thr Tyr
290
295
300
Asp Ala Tyr Gly Thr Leu Glu Glu Leu Ser Leu Phe Thr Glu Ala Val
305
310
315
320
Gln Arg Trp Asn Ile Glu Ala Val Asp Met Leu Pro Glu Tyr Met Lys
325
330
335
Leu Ile Tyr Arg Thr Leu Leu Asp Ala Phe Asn Glu Ile Glu Glu Asp
340
345
350
Met Ala Lys Gln Gly Arg Ser His Cys Val Arg Tyr Ala Lys Glu Glu
355
360
365
Asn Gln Lys Val Ile Gly Ala Tyr Ser Val Gln Ala Lys Trp Phe Ser
370
375
380
Glu Gly Tyr Val Pro Thr Ile Glu Glu Tyr Met Pro Ile Ala Leu Thr
385
390
395
400
Ser Cys Ala Tyr Thr Phe Val Ile Thr Asn Ser Phe Leu Gly Met Gly
405
410
415
Asp Phe Ala Thr Lys Glu Val Phe Glu Trp Ile Ser Asn Asn Pro Lys
420
425
430
Val Val Lys Ala Ala Ser Val Ile Cys Arg Leu Met Asp Asp Met Gln
435
440
445
Gly His Glu Phe Glu Gln Lys Arg Gly His Val Ala Ser Ala Ile Glu
450
455
460
Cys Tyr Thr Lys Gln His Gly Val Ser Lys Glu Glu Ala Ile Lys Met
465
470
475
480
Phe Glu Glu Glu Val Ala Asn Ala Trp Lys Asp Ile Asn Glu Glu Leu
485
490
495
Met Met Lys Pro Thr Val Val Ala Arg Pro Leu Leu Gly Thr Ile Leu
500
505
510
Asn Leu Ala Arg Ala Ile Asp Phe Ile Tyr Lys Glu Asp Asp Gly Tyr
515
520
525
Thr His Ser Tyr Leu Ile Lys Asp Gln Ile Ala Ser Val Leu Gly Asp
530
535
540
His Val Pro Phe
545

<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>

SEQ ID NO 5
LENGTH, 1647
TYPE, DNA
ORGANISM, Citrus X paradisi
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1) .. (789)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (793) .. (816)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (820) .. (1206)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1213) .. (1320)
OTHER INFORMATION, n is a, c,

g, or t

g, or t

g, or t

g, or t
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-continued

<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>

FEATURE,
NAME/KEY, misc_feature
LOCATION, (1324) .. (1332)
OTHER INFORMATION, n is
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1336) .. (1563)
OTHER INFORMATION, n is
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1567) .. (1575)
OTHER INFORMATION, n is
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1579) .. (1581)
OTHER INFORMATION, n is
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1588) .. (1647)
OTHER INFORMATION, n is

a, c, g, or t

a, c, g, or t

a, c, g, or t

a, c, g, or t

a, c, g, or t

<400> SEQUENCE, 5

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

60

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

120

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

180

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

240

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

300

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

360

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

420

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

480

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

540

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

600

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

660

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

720

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

780

nnnnnnnnna gannnnnnnn nnnnnnnnnn nnnnnntggn nnnnnnnnnn nnnnnnnnnn

840

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

900

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

960

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1020

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1080

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1140

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1200

nnnnnngctt acnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1260

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1320

tgcnnnnnnn nngatnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1380

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1440

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1500

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1560

nnntacnnnn nnnnngacnn ntatacgnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1620

nnnnnnnnnn nnnnnnnnnn nnnnnnn

1647
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<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>

SEQ ID NO 6
LENGTH, 1647
TYPE, DNA
ORGANISM, Citrus X paradisi
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1) .. (36)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (40) .. (795)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (799) .. (807)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (811) .. (891)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (895) .. (903)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (907) .. (1113)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1117) .. (1125)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1129) .. (1200)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1207) .. (1218)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1222) .. (1308)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1312) .. (1323)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1327) .. (1335)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1339) .. (1344)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1348) .. (1539)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1543) .. (1548)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1555) .. ( 1560)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1564) .. (1587)
OTHER INFORMATION, n is a, c,
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1591) .. ( 1647)
OTHER INFORMATION, n is a, c,

<400> SEQUENCE,

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t

g, or t
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nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnttcn nnnnnnnnnn nnnnnnnnnn

60

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

120

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

180

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

240

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

300

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

360

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

420

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

480

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

540

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

600

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

660

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

720

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

780

nnnnnnnnnn nnnnnagann nnnnnnntta nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

840

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ntccnnnnnn

900

nnngatnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

960

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1020

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1080

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnngtannnn nnnnntacnn nnnnnnnnnn

1140

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1200

agttgtnnnn nnnnnnnngt cnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1260

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnngc annnnnnnnn

1320

nnnagannnn nnnnngacnn nnnnggtnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1380

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1440

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1500

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnc ttnnnnnngc aattnnnnnn

1560

attnnnnnnn nnnnnnnnnn nnnnnnncat nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn

1620

nnnnnnnnnn nnnnnnnnnn nnnnnnn

1647

<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>

SEQ ID NO 7
LENGTH, 548
TYPE, PRT
ORGANISM, Citrus X paradisi
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1) .. (263)
OTHER INFORMATION: Xaa can be
FEATURE,
NAME/KEY, misc_feature
LOCATION, (265) .. (272)
OTHER INFORMATION: Xaa can be
FEATURE,
NAME/KEY, misc_feature
LOCATION, (274) .. (402)
OTHER INFORMATION: Xaa can be
FEATURE,
NAME/KEY, misc_feature
LOCATION, (405) .. (440)
OTHER INFORMATION: Xaa can be
FEATURE,

any naturally occurring amino acid

any naturally occurring amino acid

any naturally occurring amino acid

any naturally occurring amino acid
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<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>

NAME/KEY, misc_feature
LOCATION, (442) .. (444)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (446) .. (521)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (523) .. (525)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (527) .. (527)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (530) .. (548)
OTHER INFORMATION: Xaa

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

<400> SEQUENCE, 7

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1
5
10
15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20
25
30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35
40
45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50
55
60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65
70
75
80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
85
90
95
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
100
105
110
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
115
120
125
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
130
135
140
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
145
150
155
160
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
165
170
175
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
180
185
190
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
195
200
205
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
210
215
220
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
225
230
235
240
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
245
250
255
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
260
265
270
Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
275
280
285
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
290
295
300
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37
-continued
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
305
310
315
320
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
325
330
335
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
340
345
350
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
355
360
365
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
370
375
380

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
385
390
395
400
Xaa Xaa Ala Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
405
410
415
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
420
425
430
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Asp Xaa Xaa Xaa
435
440
445
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
450
455
460

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
465
470
475
480
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
485
490
495
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
500
505
510
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa Asp Xaa Tyr
515
520
525
Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
530
535
540
Xaa Xaa Xaa Xaa
545

<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>

SEQ ID NO 8
LENGTH, 548
TYPE, PRT
ORGANISM, Citrus X paradisi
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1) .. (12)
OTHER INFORMATION: Xaa can be
FEATURE,
NAME/KEY, misc_feature
LOCATION, (14) .. (265)
OTHER INFORMATION: Xaa can be
FEATURE,
NAME/KEY, misc_feature
LOCATION, (267) .. (269)
OTHER INFORMATION: Xaa can be
FEATURE,
NAME/KEY, misc_feature
LOCATION, (271) .. (297)
OTHER INFORMATION: Xaa can be
FEATURE,
NAME/KEY, misc_feature
LOCATION, (299) .. (301)
OTHER INFORMATION: Xaa can be
FEATURE,
NAME/KEY, misc_feature
LOCATION, (303) .. (371)
OTHER INFORMATION: Xaa can be
FEATURE,
NAME/KEY, misc_feature

any naturally occurring amino acid

any naturally occurring amino acid

any naturally occurring amino acid

any naturally occurring amino acid

any naturally occurring amino acid

any naturally occurring amino acid
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40
-continued

<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>

LOCATION, (373) .. (375)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (377) .. (400)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (403) .. (406)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (408) .. (436)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (438) .. (441)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (443) .. (445)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (447) .. (448)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (450) .. (513)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (515) .. (516)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (519) .. (520)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (522) .. (529)
OTHER INFORMATION: Xaa
FEATURE,
NAME/KEY, misc_feature
LOCATION, (531) .. (548)
OTHER INFORMATION: Xaa

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

can be any naturally occurring amino acid

<400> SEQUENCE, 8
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa
1
5
10
15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20
25
30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35
40
45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50
55
60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65
70
75
80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
85
90
95
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
100
105
110
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
115
120
125
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
130
135
140
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
145
150
155
160
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42
-continued

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
165

170

175

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
180

185

190

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
195

200

205

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
210

215

220

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
225

230

235

240

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
245

250

255

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Leu Xaa Xaa
260

265

270

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
275

280

285

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa Xaa Asp Xaa Xaa
290

295

300

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
305

310

315

320

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
325

330

335

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
340

345

350

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
355

360

365

Xaa Xaa Xaa Val Xaa Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
370

375

380

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
385

390

395

400

Ser Cys Xaa Xaa Xaa Xaa Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
405

410

415

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
420

425

430

Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Asp Xaa Xaa
435

440

445

Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
450

455

460

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
465

470

475

480

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
485

490

495

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
500

505

510

Xaa Leu Xaa Xaa Ala Ile Xaa Xaa Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa
515

520

525

Xaa His Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
530

Xaa Xaa Xaa Xaa
545

535

540
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We claim:
1. A host cell, comprising a recombinant nucleic acid
encoding a valencene synthase,
wherein the nucleic acid encoding the valencene synthase
polypeptide is heterologous to the host cell;
wherein the valencene synthase polypeptide comprises a
sequence of amino acid residues that has at least 90%
sequence identity to SEQ ID N0:4;
and wherein the host cell produces valencene.
2. The host cell of claim 1, wherein the host cell is a yeast
cell, a bacterial cell, an insect cell, or a plant cell.
3. The host cell of claim 1, wherein the nucleic acid is a
vector.
4. The host cell of claim 3, wherein the vector is a viral
vector, bacteriophage, or a plasmid.
5. A method of producing valencene, comprising:
(a) growing the host cell of any one of claim 1, 2, 3, or 4
under conditions in which the nucleic acid encoding the
valencene synthase polypeptide is expressed; and
(b) isolating the valencene produced by the host cell.
6. The method of claim 5, further comprising reacting the
valencene by a regiospecific hydroxylation and oxidation to
produce nootkatone.
7. The method of claim 5, wherein the regiospecific
hydroxylation and oxidation are catalyzed by a single multifunctional hydroxylase.
8. The method of claim 5, wherein the regiospecific
hydroxylation and oxidation are catalyzed by sequential
enzyme mediated reactions.
9. The method of any one of claims 6-8, further comprising isolating the nootkatone.

* * * * *
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